These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 19731874)

  • 21. [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease].
    Kłosiewicz-Latoszek L; Respondek W; Białobrzeska-Paluszkiewicz J; Grzybowska B; Jakóbisiak-Ostasz B; Stolarska I
    Pol Merkur Lekarski; 2003 Jul; 15(85):42-6. PubMed ID: 14593958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.
    Weinstein DL; Williams LA; Carlson DM; Kelly MT; Burns KM; Setze CM; Lele A; Stolzenbach JC
    Clin Ther; 2013 Aug; 35(8):1186-98. PubMed ID: 23891363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Managing dyslipidemia in chronic kidney disease.
    Harper CR; Jacobson TA
    J Am Coll Cardiol; 2008 Jun; 51(25):2375-84. PubMed ID: 18565393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Combined treatment: regimens, indications and safety profile].
    Muñiz Grijalvo O; Villar Ortiz J
    Clin Investig Arterioscler; 2013; 25(3):140-5. PubMed ID: 23880257
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Managing the dyslipidemia of metabolic syndrome: beyond statin therapy.
    Jialal I; Smith G
    Metab Syndr Relat Disord; 2012 Jun; 10(3):159-60. PubMed ID: 22568574
    [No Abstract]   [Full Text] [Related]  

  • 26. Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population.
    Amend KL; Landon J; Thyagarajan V; Niemcryk S; McAfee A
    Ann Pharmacother; 2011 Oct; 45(10):1230-9. PubMed ID: 21917557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The fixed combination of pravastatin and fenofibrate: what can it provide?].
    Díaz Rodríguez Á
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():12-6. PubMed ID: 25043541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Indications for the combination of pravastatin and fenofibrate according to the cardiovascular risk level. Common clinical situations].
    Pintó X
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():35-9. PubMed ID: 25043546
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined therapy in the treatment of dyslipidemia.
    Reiner Z
    Fundam Clin Pharmacol; 2010 Feb; 24(1):19-28. PubMed ID: 19682080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Statins in patients with chronic kidney disease: new evidence.
    Savino M; Garofalo C; De Paris V; Michini C; Pirro L; Palmisano R; Provenzano M; Minutolo R; Conte G; De Nicola L
    Minerva Urol Nefrol; 2013 Sep; 65(3):217-23. PubMed ID: 23872633
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia.
    Goldberg AC; Bittner V; Pepine CJ; Kelly MT; Thakker K; Setze CM; Lele A; Sleep DJ
    Am J Cardiol; 2011 Mar; 107(6):898-905. PubMed ID: 21247520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expert commentary: the safety of fibrates in lipid-lowering therapy.
    Brown WV
    Am J Cardiol; 2007 Mar; 99(6A):19C-21C. PubMed ID: 17368273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A clinical puzzle: fibrates and homocysteine elevation: editorial to: "fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine" by M. Lever et al.
    Davidson MH
    Cardiovasc Drugs Ther; 2009 Oct; 23(5):341-2. PubMed ID: 19844785
    [No Abstract]   [Full Text] [Related]  

  • 34. [Clinical practice guidelines for the management of dyslipidemia in chronic kidney disease].
    Shoji T
    Nihon Jinzo Gakkai Shi; 2013; 55(7):1267-75. PubMed ID: 24288962
    [No Abstract]   [Full Text] [Related]  

  • 35. [The combinations of statins and fibrates: pharmacokinetic and clinical implications].
    González Santos P
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():7-11. PubMed ID: 25043540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Should we use statins in all patients with chronic kidney disease without dialysis therapy? The current state of knowledge.
    Rysz J; Gluba-Brzózka A; Banach M; Więcek A
    Int Urol Nephrol; 2015 May; 47(5):805-13. PubMed ID: 25758011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of dyslipidemia to reduce cardiovascular risk in patients with multiple risk factors.
    Ballantyne CM
    Clin Cornerstone; 2007; 8 Suppl 6():S6-13. PubMed ID: 17948362
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The dyslipidemia of chronic renal disease: effects of statin therapy.
    Ozsoy RC; van Leuven SI; Kastelein JJ; Arisz L; Koopman MG
    Curr Opin Lipidol; 2006 Dec; 17(6):659-66. PubMed ID: 17095911
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of fibrate-statin combination therapy compared to fibrate monotherapy in patients with dyslipidemia: a meta-analysis.
    Choi HD; Shin WG; Lee JY; Kang BC
    Vascul Pharmacol; 2015; 65-66():23-30. PubMed ID: 25451563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of dyslipidemia in patients with chronic kidney disease.
    Marino A; Tannock LR
    Postgrad Med; 2013 Jul; 125(4):28-37. PubMed ID: 23842535
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.